Background: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is defined only in adults older than 50 years. However, EBV-positive DLBCL can affect younger patients. We investigated the prevalence, clinical characteristics and survival outcomes of EBV-positive DLBCL in young adults.
clinical features and outcomes compared with EBV-positive DLBCL of the elderly?
Experience with Hodgkin lymphoma (HL) showed overall that patients with EBV-positive HL had a poorer outcome than those with EBV-negative HL. However, this poorer outcome was confined to the older age group (>50 years) [13] . Most of the reports have described similar or even better survival of younger patients with EBV-positive HL compared with younger patients with EBV-negative HL [13] .
In this study, we investigated the prevalence of EBV-positive DLBCL in young adults and analyzed the differential effect of EBV status on clinical characteristics and survival outcomes in DLBCL patients according to age group.
patients and methods patients
Patients who met the following criteria were included in the study: (i) pathology-confirmed de novo DLBCL, according to the WHO classification; (ii) registered in the Samsung Medical Center (SMC) retrospective lymphoma cohort and prospective SMC Lymphoma Cohort Study I (ClinicalTrials.gov Identifier: NCT00822731) (1995-2011); (iii) adequate amount and quality of paraffin-embedded biopsy specimens or unstained slides for EBV-encoded RNA (EBER) in situ hybridization (ISH). Patients with unknown EBV status, primary central nervous system lymphoma, post-transplant lymphoproliferative disorders, and HIV-positive DLBCL were excluded from the study. This study was approved by the Institutional Review Boards at SMC and Asan Medical Center, in accordance with the Declaration of Helsinki. This study is registered with ClinicalTrials.gov, Identifier: NCT02060435. pathology All pathology specimens were reviewed by experienced hematopathologists (M.E.H. and Y.H.K. at SMC and J.H. at AMC). For immunohistochemical staining, we used a panel of monoclonal antibodies against CD20, CD3, CD10, BCL-6, BCL-2, IRF4/MUM-1, and Ki67. The patients were classified into germinal center B-cell-like (GCB) and non-germinal center B-cell-like (non-GCB) subtypes using the Hans algorithm [14] .
EBV RNA was detected by an ISH technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL). A positive reaction was defined as more than 20% of examined cells showing nuclear positivity [6] .
statistical analysis
Intergroup comparisons were carried out with Fisher's exact test for categorical variables and the Mann-Whitney U test for age. For survival analysis, we carried out Kaplan-Meier and multivariate proportional hazard (Cox) analyses. Statistical analyses were carried out using the software package IBM PASW version 18.0 (SPSS, Inc., Chicago, IL). Other detailed methods are described in the supplementary Data S1, available at Annals of Oncology online.
molecular inversion probe assay
We carried out the molecular inversion probe (MIP) assay for 38 patients with DLBCL to clarify the molecular genetics of EBV-positive DLBCL compared with EBV-negative DLBCL (unpublished data) [15] . We carried out subset analysis of 17 EBV-positive DLBCL patients among these 38 patients, according to age group (≤50 versus >50 years). Other detailed methods are described in the supplementary Data S1, available at Annals of Oncology online.
microarray gene expression profiling
We have reported the gene expression profiles of 164 patients with DLBCL using the whole-genome cDNA-mediated Annealing, Selection, and Ligation (WG-DASL) assay (Illumina, San Diego, CA) [16, 17] . Among 164 patients, we carried out supplemental analysis of 16 EBV-positive DLBCL patients according to age groups (≤60 versus >60 years). Other detailed methods are described in the supplementary Data S1, available at Annals of Oncology online.
results

patients characteristics
A total of 571 cases who met inclusion criteria were included in the analysis as the whole cohort. Of these 571 cases with DLBCL, 48 (8.4%) showed EBV positivity. In the young group, the prevalence of EBV positivity was 6.7% (13/195 ). In the elderly group, the prevalence of EBV positivity was 9.3% (35/ 376) ( Figure 1 ).
In the whole cohort, EBV positivity was closely associated with older age, more advanced stage, two or more sites of extranodal involvement, higher IPI risk group, and higher age-adjusted IPI risk group. The complete response rate to frontline chemotherapy in the EBV-positive DLBCL group (69.0%) was significantly worse than that of the EBV-negative DLBCL group (83.6%) (P = 0.032). In the young group, patients with EBV-positive DLBCL did not demonstrate unique clinical characteristics compared with patients with EBV-negative DLBCL. However, in the elderly group, patients with EBV-positive DLBCL retained their unique and unfavorable clinical characteristics (Table 1 ).
prognostic value of EBV status on survival according to age groups
After a median follow-up duration of 102.5 (range, 39.6-235.7) months, the overall 5-year OS and PFS rates were 68.7% and 62.2%, respectively. In the whole cohort (N = 571), the EBVpositive DLBCLs showed substantially worse OS (median OS, 17.3 versus 192.6 months, P < 0.001) and PFS (median PFS, 8.6 versus 149.9 months, P < 0.001) compared with the EBV-negative DLBCLs (Figure 2A and B). We carried out subgroup analysis based on age group [young (≤50 years) and elderly (>50 years)]. In the young group, there was no significant difference in median OS (median OS, both not reached, P = 0.751) and PFS (median PFS, both not reached, P = 0.377) between two groups ( Figure 2C and D). In the elderly group, EBV-positive DLBCLs were significantly associated with worse OS (median OS, 12.5 versus 131.1 months, P < 0.001) and PFS (median PFS, 8.0 versus 102.7 months, P < 0.001) compared with EBV-negative DLBCLs (Figure 2E and F).
In the present era of rituximab treatment of DLBCL, we carried out subset analysis in the SMC Lymphoma Cohort I [ prospectively collected and uniformly treated (R-CHOP) cohort]. Among 322 patients in the SMC Lymphoma Cohort I, there were 216 patients for whom EBV status data were available, and these were included in the 'prospective (R-CHOP) cohort'. There was no significant difference of baseline characteristics between the whole cohort and the prospective (R-CHOP) cohort (supplementary Table S1 , available at Annals of Oncology online). In the young group of the prospective Figure 3C and D). However, in the elderly group, EBV-positive DLBCL was significantly associated with worse OS (median OS, 7.0 months versus not reached, P < 0.001) and PFS (median PFS, 6.9 versus not reached, P < 0.001) compared with the EBVnegative DLBCLs ( Figure 3E and F).
For external validation, we identified 15 patients with EBVpositive DLBCL in the young group (≤50 years) from the AMC medical database, who were all treated with R-CHOP chemotherapy. We carried out a matched-pair analysis at a ratio of 1 : 2. The source of matching was the EBV-negative DLBCL patients in the young group (≤50 years) from the SMC Lymphoma Cohort Study I. Patients were matched according to age, sex, and IPI risk group (0-5). Matched-pair analysis also reaffirmed that there was no significant difference in survival outcomes between EBV-positive DLBCL and EBV-negative DLBCL in the young group (supplementary Figure S1 , available at Annals of Oncology online).
prognostic factor analyses
The clinical factors associated with worse OS in univariate analysis were as follows: EBV positivity, age older than 50 years, poor performance status, advanced stage, elevated lactic dehydrogenase, and two or more sites of extranodal involvement. Multivariate analysis showed that EBV positivity in the elderly Bold value indicates P < 0.05. Data were missing as follows: Ann Arbor stage (n = 9), no. of extranodal involvement (n = 10), lactic dehydrogenase (n = 13), BM involvement (n = 10), response to frontline Tx (n = 48), and histologic subtype (n = 22 This effect proved to be independent of poor performance status, advanced stage, elevated lactic dehydrogenase, and two or more sites of extranodal involvement. In the young group, EBV positivity did not affect OS in either the whole cohort (HR 1.17; 95% CI 0.35-3.89; P = 0.801) or the prospective (R-CHOP) cohort (HR NA; 95% CI NA; P = 0.992) ( Table 2 ).
copy number alterations in EBV-positive DLBCLs according to age groups
Copy number alterations in both young (N = 4) and elderly (N = 13) EBV-positive DLBCLs were demonstrated in supplementary Figure S1 , available at Annals of Oncology online. Generally, elderly EBV-positive DLBCL patients showed a tendency of more frequent copy number variations. Two cases in the young group showed chromosome 18q arm loss (red arrow in supplementary Figure S2 , available at Annals of Oncology online). We carried out permutation t-test to discover the probes that are differentially expressed between young age group and elderly group in 16 EBV-positive DLBCL patients. The result demonstrated that no specific tendency exists in the gene expression profiles between 6 young EBV-positive DLBCLs and 10 elderly EBV-positive DLBCLs (supplementary Figure S3 , available at Annals of Oncology online).
discussion
Important mechanisms in lymphomagenesis of EBV-positive DLBCL of the elderly are thought to be attributable to oncogenic pathway activation mainly via latent membrane protein-1 (LMP-1) and evasion of immune system as a result of immunosenescence [18, 19] . Immunosenescence represents age-dependent dysfunction of the immune system and can be characterized by decreased cytotoxic T-cell effector responses, deficits in adaptive immunity, and impaired control of latent EBV infection [19] . [10, 20] . We raised the following questions: (i) Is EBV-positive DLBCL of the elderly really a disease only of the elderly? If not, what is the prevalence of EBV-positive DLBCL in young adults? (ii) Does EBV positivity in young adults with DLBCL also have unfavorable prognostic impact on survival as shown in EBV-positive DLBCL of the elderly? (iii) Can EBV-positive DLBCL in young adults be considered as a clinically distinct disease entity from EBV-positive DLBCL of the elderly? (iv) Are there possibly distinct mechanisms of lymphomagenesis of EBV-positive DLBCL in young, immunocompetent adults other than mechanisms of immunosenescence?
We found that 8.4% (48/571) of DLBCL patients in the whole cohort showed EBV positivity, an incidence comparable with the results of previous Asian studies [6, 9, 11] . Notably, the prevalence of EBV positivity in the 195 DLBCL patients in the young age group was 6.7% (13/195 ). To our knowledge, this is the first report of the prevalence of EBV-positive DLBCL in young adults, and we suggest that EBV-positive DLBCL of the elderly is not really a disease confined to older people. Despite the retrospective nature of this study, we consider that the incidence of EBV-positive DLBCL in young adults might be higher than expected, and we also suggest that a consensus is needed on the necessity of EBV screening in DLBCL is needed for young adult patients.
EBV positivity in DLBCL has been associated with worse outcomes in most previous studies, especially in Asian populations. However, a recent study by Ok et al. did not show unique clinical characteristics or worse outcomes in Caucasian patients with EBV-positive DLBCL [21] . Of note, DLBCL that co-expressed CD30 and EBER showed worse outcomes in the study by Ok et al. [21] . We suggest that the different prevalence of EBVpositive DLBCL and the geographical genetic variation in the EBV genome should be considered as factors in this difference.
Our results confirmed that the poor prognostic impact of EBV positivity is effective and consistent in Asian populations. A recent study of 260 Japanese DLBCL patients by Sato et al. also supported the poor prognostic impact of EBV positivity [22] . Notably, the current study did not demonstrate unfavorable baseline characteristics or poor prognostic impact of EBV positivity in young adult DLBCL patients, while EBV positivity in elderly DLBCL patients was significantly associated with unique baseline characteristics and poor survival outcomes. Interestingly, this phenomenon has been observed in previous studies of HL [13] . This may be attributable to the differential effects of EBV status in different age-defined patient subgroups. Therefore, we propose that EBV-positive DLBCL in young adults can be considered to be clinically distinct from EBV-positive DLBCL of the elderly, and that there may be different mechanisms of lymphomagenesis in EBV-positive DLBCL in young adults. However, our findings are based on a relatively small numbers of patients; therefore, these findings need to be confirmed on a large cohort.
In the MIP and WG-DASL assay, the sample size was small and it is hard to find specific differences of genetic alterations between the two groups. There was only a slight tendency of more frequent copy number variations in elderly EBV-positive DLBCL patients. We found two cases in the young group who showed chromosome 18q arm loss in common. Even though these are preliminary results, we consider that this study emphasizes further investigation to search for differences in molecular and genetic alterations between young and elderly EBV-positive DLBCL patients.
This study confirmed that a substantial proportion of EBVpositive DLBCL of the elderly can occur in young adults. Moreover, this study showed that EBV positivity of DLBCL in young adults did not predict unfavorable clinical characteristics or worse outcomes. We suggest that EBV-positive DLBCL in young adults might be a clinically distinct disease entity from EBV-positive DLBCL of the elderly, and that there could be substantially different mechanisms, other than immunosenescence, of lymphomagenesis in EBV-positive DLBCL in young adults. Further studies are needed to identify the optimal cutoff value for EBER positivity and the age criterion to validate these results in different ethnic groups. We also suggest that the current designation of EBV-positive DLBCL confined only in the elderly needs to be modified in the next version of the WHO classification. 
